News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Senesco Technologies, Inc. (SNT)'s Drug Candidate SNS01-T Selectively Kills Cancer Cells And Not Healthy Cells In Disease Models



12/10/2013 10:52:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) reported results of preclinical studies with SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES